People · Operator
Named in public records as an officer, director or promoter · active 2012–2013 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Akari Therapeutics Plc | — | Biotechnology | Series C | $140.5M | $34.1M | 2012 |
AMOS EIRAN at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside AMOS EIRAN on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Samir Patel | 1 | 7 |
| David Sidransky | 1 | 7 |
| Hoyoung Huh | 1 | 7 |
| James Hill | 1 | 6 |
| MARK COHEN | 1 | 5 |
| Wendy DiCicco | 1 | 4 |
| Donald Williams | 1 | 4 |
| Yuval Cohen | 1 | 4 |
| Johnson Lau | 1 | 3 |
| DOV ELEFANT | 1 | 3 |
| Allan Shaw | 1 | 2 |
| GILEAD RADAY | 1 | 2 |
| Gur Roshwalb | 1 | 2 |
| Fredric Price | 1 | 2 |
| Robert Doman | 1 | 2 |
| Wa'el Hashad | 1 | 2 |
| Michael Grissinger | 1 | 2 |
| Torsten Hombeck | 1 | 2 |
| David Byrne | 1 | 2 |
| SAUL YEDGAR | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.